Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date		09682488	
			2001-09-07	
	First Named Inventor	Micha	ael G. Lamming	
	Art Unit		2157	
	Examiner Name	Avi N	f. Gold	
	Attorney Docket Number		A0849-US-NP	

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wisl	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
	U.S.PATENT APPLICATION PUBLICATIONS Remove									
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines where ant Passages or Releves Appear	
	1									
If you wis	h to a	l dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Ad	d button	Add	
				FOREIG	3N PAT	TENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	ть
	1	1120701	EP		A1	2001-08-01	I-Data Internationa	ı A/S		
	2	1291787	EP		А3	2006-03-15	Xerox Corporation			
	3									

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON DATENT LITERATURE DOCUMENTS. Remove						
	Attorney Docket Numb	er	A0849-US-NP			
(Examiner Name	Avi N	A. Gold			
(Not for submission under 37 CFR 1.99)	Art Unit		2157			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	First Named Inventor Michael G, Lamming				
INFORMATION DIGGL COURT	Filing Date		2001-09-07			

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Application Number

publisher, city and/or country where published.

Examiner Cite

Initials* No.

09682488

T5

1							
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner Signature	Date	te Considered					
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a							

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patient Documents at www.USPTO.GGO of MPEP 801.84. Tester office that issued the document, by the law document, by the law of the time of the patient of the patient document of the patient document. The should be considered to the consideration of the patient document. The patient document is not considered to the consideration of the patient document.

1 See Patient Description of the patient document of the patient document of the patient document. The patient is not patient document of the patient document document of the patient document

	Application Number		09682488	
OUDE	Filing Date		2001-09-07	
SURE	First Named Inventor Mich		hael G. Lamming	
CAN I R 1.99)	Art Unit		2157	
,	Examiner Name Avi N		1. Gold	
	Attorney Docket Number		A0849-US-NP	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

INFORMATION DISCLO STATEMENT BY APPLI (Not for submission under 37 Cl

	That each item of information contained in the information disclosure statement was first cited in any communication
✓	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
	information disclosure statement

OR

That no item of information contained in the information disclosure statement was cited in a communication from a
foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
statement.

See attached certification statement.

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Thomas Zell/	Date (YYYY-MM-DD)	2006-04-12
Name/Print	Thomas Zell	Registration Number	37481

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Rox 1450. Alexandria VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 95.579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan, Office may not process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademan, Office may not be able to process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552/ami.
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make identifications about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CPR 114, as a routine use, to the public if the record was filed in a papication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application one on the public rescendence or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.